|
1
|
Amant F, Moerman P, Neven P, Timmerman D,
Van LE and Vergote I: Endometrial cancer. Lancet. 366:491–505.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Leslie KK, Thiel KW, Goodheart MJ, De
Geest K, Jia Y and Yang S: Endometrial cancer. Obstet Gynecol Clin
North Am. 39:255–268. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Merritt MA and Cramer DW: Molecular
pathogenesis of endometrial and ovarian cancer. Cancer Biomark.
9:287–305. 2010.
|
|
4
|
Troisi R, Potischman N, Hoover RN, Siiteri
P and Brinton LA: Insulin and endometrial cancer. Am J Epidemiol.
146:476–482. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bednarek AK, Laflin KJ, Daniel RL, Liao Q,
Hawkins KA and Aldaz CM: WWOX, a novel WW domain-containing protein
mapping to human chromosome 16q23.3–24.1, a region frequently
affected in breast cancer. Cancer Res. 60:2140–2145.
2000.PubMed/NCBI
|
|
6
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Garg M: Epithelial-mesenchymal transition
- activating transcription factors - multifunctional regulators in
cancer. World J Stem Cells. 5:188–195. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tanaka Y, Terai Y, Kawaguchi H, Fujiwara
S, Yoo S, Tsunetoh S, Takai M, Kanemura M, Tanabe A and Ohmichi M:
Prognostic impact of EMT
(epithelial-mesenchymal-transition)-related protein expression in
endometrial cancer. Cancer Biol Ther. 14:13–19. 2013. View Article : Google Scholar :
|
|
10
|
Huber MA, Kraut N and Beug H: Molecular
requirements for epithelial-mesenchymal transition during tumor
progression. Curr Opin Cell Biol. 17:548–558. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Thiery JP: Epithelial-mesenchymal
transitions in development and pathologies. Curr Opin Cell Biol.
15:740–746. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Grünert S, Jechlinger M and Beug H:
Diverse cellular and molecular mechanisms contribute to epithelial
plasticity and metastasis. Nat Rev Mol Cell Biol. 4:657–665. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Montserrat N, Mozos A, Llobet D, Dolcet X,
Pons C, de Herreros AG, Matias-Guiu X and Prat J: Epithelial to
mesenchymal transition in early stage endometrioid endometrial
carcinoma. Hum Pathol. 43:632–643. 2012. View Article : Google Scholar
|
|
14
|
Abal M, Llauradó M, Doll A, Monge M, Colas
E, González M, Rigau M, Alazzouzi H, Demajo S, Castellví J, et al:
Molecular determinants of invasion in endometrial cancer. Clin
Transl Oncol. 9:272–277. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Aqeilan RI, Donati V, Palamarchuk A,
Trapasso F, Kaou M, Pekarsky Y, Sudol M and Croce CM: WW
domain-containing proteins, WWOX and YAP, compete for interaction
with ErbB-4 and modulate its transcriptional function. Cancer Res.
65:6764–6772. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Aqeilan RI, Donati V, Gaudio E, Nicoloso
MS, Sundvall M, Korhonen A, Lundin J, Isola J, Sudol M, Joensuu H,
et al: Association of Wwox with ErbB4 in breast cancer. Cancer Res.
67:9330–9336. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Aqeilan RI, Palamarchuk A, Weigel RJ,
Herrero JJ, Pekarsky Y and Croce CM: Physical and functional
interactions between the Wwox tumor suppressor protein and the
AP-2gamma transcription factor. Cancer Res. 64:8256–8261. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Guler G, Huebner K, Himmetoglu C, Jimenez
RE, Costinean S, Volinia S, Pilarski RT, Hayran M and Shapiro CL:
Fragile histidine triad protein, WW domain-containing
oxidoreductase protein Wwox, and activator protein 2gamma
expression levels correlate with basal phenotype In breast cancer.
Cancer. 115:899–908. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gaudio E, Palamarchuk A, Palumbo T,
Trapasso F, Pekarsky Y, Croce CM and Aqeilan RI: Physical
association with WWOX suppresses c-Jun transcriptional activity.
Cancer Res. 66:11585–11589. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Abu-Remaileh M and Aqeilan RI: Tumor
suppressor WWOX regulates glucose metabolism via HIF1α modulation.
Cell Death Differ. 21:1805–1814. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Abu-Odeh M, Bar-Mag T, Huang H, Kim T,
Salah Z, Abdeen SK, Sudol M, Reichmann D, Sidhu S, Kim PM, et al:
Characterizing WW domain interactions of tumor suppressor WWOX
reveals its association with multiprotein networks. J Biol Chem.
289:8865–8880. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sałuda-Gorgul A, Seta K, Nowakowska M and
Bednarek AK: WWOX oxidoreductase - substrate and enzymatic
characterization. Z Naturforsch C. 66:73–82. 2011. View Article : Google Scholar
|
|
23
|
Aqeilan RI, Hagan JP, de Bruin A, Rawahneh
M, Salah Z, Gaudio E, Siddiqui H, Volinia S, Alder H, Lian JB, et
al: Targeted ablation of the WW domain-containing oxidoreductase
tumor suppressor leads to impaired steroidogenesis. Endocrinology.
150:1530–1535. 2009. View Article : Google Scholar :
|
|
24
|
Aqeilan RI and Croce CM: WWOX in
biological control and tumorigenesis. J Cell Physiol. 212:307–310.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Qin HR, Iliopoulos D, Semba S, Fabbri M,
Druck T, Volinia S, Croce CM, Morrison CD, Klein RD and Huebner K:
A role for the WWOX gene in prostate cancer. Cancer Res.
66:6477–6481. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nunez MI, Rosen DG, Ludes-Meyers JH, Abba
MC, Kil H, Page R, Klein-Szanto AJ, Godwin AK, Liu J, Mills GB, et
al: WWOX protein expression varies among ovarian carcinoma
histotypes and correlates with less favorable outcome. BMC Cancer.
5:642005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kosla K, Pluciennik E, Kurzyk A,
Jesionek-Kupnicka D, Kordek R, Potemski P and Bednarek AK:
Molecular analysis of WWOX expression correlation with
proliferation and apoptosis in glioblastoma multiforme. J
Neurooncol. 101:207–213. 2011. View Article : Google Scholar :
|
|
28
|
Kuroki T, Yendamuri S, Trapasso F,
Matsuyama A, Aqeilan RI, Alder H, Rattan S, Cesari R, Nolli ML,
Williams NN, et al: The tumor suppressor gene WWOX at FRA16D is
involved in pancreatic carcinogenesis. Clin Cancer Res.
10:2459–2465. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Płuciennik E, Nowakowska M, Wujcicka WI,
Sitkiewicz A, Kazanowska B, Zielińska E and Bednarek AK: Genetic
alterations of WWOX in Wilms’ tumor are involved in its
carcinogenesis. Oncol Rep. 28:1417–1422. 2012.
|
|
30
|
Żelazowski MJ, Płuciennik E, Pasz-Walczak
G, Potemski P, Kordek R and Bednarek AK: WWOX expression in
colorectal cancer - a real-time quantitative RT-PCR study. Tumor
Biol. 32:551–560. 2011. View Article : Google Scholar
|
|
31
|
Li YP, Wu CC, Chen WT, Huang YC and Chai
CY: The expression and significance of WWOX and β-catenin in
hepatocellular carcinoma. APMIS. 121:120–126. 2013. View Article : Google Scholar
|
|
32
|
Xiong Z, Hu S and Wang Z: Cloning of WWOX
gene and its growth-inhibiting effects on ovarian cancer cells. J
Huazhong Univ Sci Technolog Med Sci. 30:365–369. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Qu J, Lu W, Li B, Lu C and Wan X: WWOX
induces apoptosis and inhibits proliferation in cervical cancer and
cell lines. Int J Mol Med. 31:1139–1147. 2013.PubMed/NCBI
|
|
34
|
Bednarek AK, Keck-Waggoner CL, Daniel RL,
Laflin KJ, Bergsagel PL, Kiguchi K, Brenner AJ and Aldaz CM: WWOX,
the FRA16D gene, behaves as a suppressor of tumor growth. Cancer
Res. 61:8068–8073. 2001.PubMed/NCBI
|
|
35
|
Gourley C, Paige AJ, Taylor KJ, Ward C,
Kuske B, Zhang J, Sun M, Janczar S, Harrison DJ, Muir M, et al:
WWOX gene expression abolishes ovarian cancer tumorigenicity in
vivo and decreases attachment to fibronectin via integrin alpha3.
Cancer Res. 69:4835–4842. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Nowakowska M, Pospiech K, Lewandowska U,
Piastowska-Ciesielska AW and Bednarek AK: Diverse effect of WWOX
overexpression in HT29 and SW480 colon cancer cell lines. Tumor
Biol. 35:9291–9301. 2014. View Article : Google Scholar
|
|
37
|
Lewandowska U, Zelazowski M, Seta K,
Byczewska M, Pluciennik E and Bednarek AK: WWOX, the tumor
suppressor gene affected in multiple cancers. J Physiol Pharmacol.
60(Suppl 1): 47–56. 2009.
|
|
38
|
Płuciennik E, Kośla K, Wójcik-Krowiranda
K, Bieńkiewicz A and Bednarek AK: The WWOX tumor suppressor gene in
endometrial adenocarcinoma. Int J Mol Med. 32:1458–1464. 2013.
|
|
39
|
Pecorelli S: Revised FIGO staging for
carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol
Obstet. 105:103–104. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Mo B, Vendrov AE, Palomino WA, DuPont BR,
Apparao KB and Lessey BA: ECC-1 cells: A well-differentiated
steroid-responsive endometrial cell line with characteristics of
luminal epithelium. Biol Reprod. 75:387–394. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Pfaffl MW, Horgan GW and Dempfle L:
Relative expression software tool (REST) for group-wise comparison
and statistical analysis of relative expression results in
real-time PCR. Nucleic Acids Res. 30:e362002. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sakuragi N, Nishiya M, Ikeda K, Ohkouch T,
Furth EE, Hareyama H, Satoh C and Fujimoto S: Decreased E-cadherin
expression in endometrial carcinoma is associated with tumor
dedifferentiation and deep myometrial invasion. Gynecol Oncol.
53:183–189. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Płuciennik E, Kusińska R, Potemski P,
Kubiak R, Kordek R and Bednarek AK: WWOX - the FRA16D cancer gene:
Expression correlation with breast cancer progression and
prognosis. Eur J Surg Oncol. 32:153–157. 2006. View Article : Google Scholar
|
|
44
|
Wang X, Chao L, Ma G, Chen L, Zang Y and
Sun J: The prognostic significance of WWOX expression in patients
with breast cancer and its association with the basal-like
phenotype. J Cancer Res Clin Oncol. 137:271–278. 2011. View Article : Google Scholar
|
|
45
|
Spoelstra NS, Manning NG, Higashi Y,
Darling D, Singh M, Shroyer KR, Broaddus RR, Horwitz KB and Richer
JK: The transcription factor ZEB1 is aberrantly expressed in
aggressive uterine cancers. Cancer Res. 66:3893–3902. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Singh M, Spoelstra NS, Jean A, Howe E,
Torkko KC, Clark HR, Darling DS, Shroyer KR, Horwitz KB, Broaddus
RR, et al: ZEB1 expression in type I vs type II endometrial
cancers: A marker of aggressive disease. Mod Pathol. 21:912–923.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yan H and Sun Y: Evaluation of the
mechanism of epithelial-mesenchymal transition in human ovarian
cancer stem cells transfected with a WW domain-containing
oxidoreductase gene. Oncol Lett. 8:426–430. 2014.PubMed/NCBI
|
|
48
|
Palumbo JS, Kombrinck KW, Drew AF, Grimes
TS, Kiser JH, Degen JL and Bugge TH: Fibrinogen is an important
determinant of the metastatic potential of circulating tumor cells.
Blood. 96:3302–3309. 2000.PubMed/NCBI
|
|
49
|
Sahni A, Arévalo MT, Sahni SK and
Simpson-Haidaris PJ: The VE-cadherin binding domain of fibrinogen
induces endothelial barrier permeability and enhances
transendothelial migration of malignant breast epithelial cells.
Int J Cancer. 125:577–584. 2009. View Article : Google Scholar : PubMed/NCBI
|
